Abstract
The diagnosis of clinically amyopathic dermatomyositis (CADM) essentially depends on cutaneous manifestations. The early diagnosis of CADM associated with the anti‐melanoma differentiation‐associated protein‐5 (MDA5) antibody is especially important because it includes a subset of patients highly at risk for rapidly progressive interstitial lung disease (RP‐ILD) with potentially fatal outcomes. Moreover, the recognition of distinctive rashes for anti‐MDA5 antibody‐positive DM can greatly aid in distinguishing from other DM subsets since serological anti‐MDA5 antibody testing is not yet widely accessible.
This article is protected by copyright. All rights reserved.
https://ift.tt/2zeU2ns
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου